203 related articles for article (PubMed ID: 12442346)
1. Pegylated liposomal doxorubicin (Doxil) for metastatic breast cancer: the Cancer Research Network, Inc., experience.
Perez AT; Domenech GH; Frankel C; Vogel CL
Cancer Invest; 2002; 20 Suppl 2():22-9. PubMed ID: 12442346
[TBL] [Abstract][Full Text] [Related]
2. Reduced incidence of severe palmar-plantar erythrodysesthesia and mucositis in a prospective multicenter phase II trial with pegylated liposomal doxorubicin at 40 mg/m2 every 4 weeks in previously treated patients with metastatic breast cancer.
Al-Batran SE; Meerpohl HG; von Minckwitz G; Atmaca A; Kleeberg U; Harbeck N; Lerbs W; Hecker D; Sehouli J; Knuth A; Jager E
Oncology; 2006; 70(2):141-6. PubMed ID: 16645327
[TBL] [Abstract][Full Text] [Related]
3. Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma.
Lyass O; Uziely B; Ben-Yosef R; Tzemach D; Heshing NI; Lotem M; Brufman G; Gabizon A
Cancer; 2000 Sep; 89(5):1037-47. PubMed ID: 10964334
[TBL] [Abstract][Full Text] [Related]
4. A dose-escalating pilot study of sterically stabilized, pegylated liposomal doxorubicin (Lipo-Dox) in patients with metastatic breast cancer.
Chao TC; Wang WS; Yen CC; Chiou TJ; Liu JH; Chen PM
Cancer Invest; 2003; 21(6):837-47. PubMed ID: 14735687
[TBL] [Abstract][Full Text] [Related]
5. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer.
O'Brien ME; Wigler N; Inbar M; Rosso R; Grischke E; Santoro A; Catane R; Kieback DG; Tomczak P; Ackland SP; Orlandi F; Mellars L; Alland L; Tendler C;
Ann Oncol; 2004 Mar; 15(3):440-9. PubMed ID: 14998846
[TBL] [Abstract][Full Text] [Related]
6. Incidence of palmar-plantar erythrodysesthesia in pretreated and unpretreated patients receiving pegylated liposomal doxorubicin.
Miolo G; Baldo P; Bidoli E; Lombardi D; Scalone S; Sorio R; Veronesi A
Tumori; 2009; 95(6):687-90. PubMed ID: 20210230
[TBL] [Abstract][Full Text] [Related]
7. A randomised phase II study of two different schedules of pegylated liposomal doxorubicin in metastatic breast cancer (EORTC-10993).
Coleman RE; Biganzoli L; Canney P; Dirix L; Mauriac L; Chollet P; Batter V; Ngalula-Kabanga E; Dittrich C; Piccart M
Eur J Cancer; 2006 May; 42(7):882-7. PubMed ID: 16520033
[TBL] [Abstract][Full Text] [Related]
8. Pegylated liposomal doxorubicin with vinorelbine in metastatic breast carcinoma. A phase I-II clinical investigation.
Gebbia V; Mauceri G; Fallica G; Borsellino N; Tirrito ML; Testa A; Varvara F; Colombo A; Ferrera P
Oncology; 2002; 63(1):23-30. PubMed ID: 12187067
[TBL] [Abstract][Full Text] [Related]
9. Biweekly Pegylated Liposomal Doxorubicin (Caelyx) in Heavily Pretreated Metastatic Breast Cancer: A Phase 2 Study.
Jehn CF; Hemmati P; Lehenbauer-Dehm S; Kümmel S; Flath B; Schmid P
Clin Breast Cancer; 2016 Dec; 16(6):514-519. PubMed ID: 27395417
[TBL] [Abstract][Full Text] [Related]
10. Pegylated liposomal doxorubicin in elderly patients with metastatic breast cancer.
Minisini AM; Andreetta C; Fasola G; Puglisi F
Expert Rev Anticancer Ther; 2008 Mar; 8(3):331-42. PubMed ID: 18366282
[TBL] [Abstract][Full Text] [Related]
11. Pegylated liposomal doxorubicin: optimizing the dosing schedule in ovarian cancer.
Rose PG
Oncologist; 2005 Mar; 10(3):205-14. PubMed ID: 15793224
[TBL] [Abstract][Full Text] [Related]
12. A phase-I study evaluating the combination of pegylated liposomal doxorubicin and paclitaxel as salvage chemotherapy in metastatic breast cancer previously treated with anthracycline.
Hong RL; Lin CH; Chao TY; Kao WY; Wang CH; Hsieh RK; Hwang WS
Cancer Chemother Pharmacol; 2008 Apr; 61(5):847-53. PubMed ID: 17609947
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of pegylated liposomal doxorubicin: inactive in recurrent small-cell lung cancer. A Hellenic Cooperative Oncology Group Study.
Samantas E; Kalofonos H; Linardou H; Nicolaides C; Mylonakis N; Fountzilas G; Kosmidis P; Skarlos D
Ann Oncol; 2000 Nov; 11(11):1395-7. PubMed ID: 11142478
[TBL] [Abstract][Full Text] [Related]
14. Maintenance treatment with pegylated liposomal doxorubicin versus observation following induction chemotherapy for metastatic breast cancer: GEICAM 2001-01 study.
Alba E; Ruiz-Borrego M; Margelí M; Rodríguez-Lescure A; Sánchez-Rovira P; Ruiz A; Mel-Lorenzo JR; Ramos-Vázquez M; Ribelles N; Calvo E; Casado A; Márquez A; Vicente D; García-Sáenz JA; Martín M
Breast Cancer Res Treat; 2010 Jul; 122(1):169-76. PubMed ID: 20361253
[TBL] [Abstract][Full Text] [Related]
15. Pegylated liposomal doxorubicin in combination with vinorelbine as salvage treatment in pretreated patients with advanced breast cancer: a multicentre phase II study.
Ardavanis A; Mavroudis D; Kalbakis K; Malamos N; Syrigos K; Vamvakas L; Kotsakis A; Kentepozidis N; Kouroussis C; Agelaki S; Georgoulias V;
Cancer Chemother Pharmacol; 2006 Dec; 58(6):742-8. PubMed ID: 16718470
[TBL] [Abstract][Full Text] [Related]
16. Bi-weekly liposomal doxorubicin for advanced breast cancer in elderly women (≥ 70 years).
Basso U; Roma A; Brunello A; Falci C; Fiduccia P; Banzato A; Bononi A; Gusella M; Vamvakas L; Zagonel V; Monfardini S
J Geriatr Oncol; 2013 Oct; 4(4):340-5. PubMed ID: 24472477
[TBL] [Abstract][Full Text] [Related]
17. EORTC 10968: a phase I clinical and pharmacokinetic study of polyethylene glycol liposomal doxorubicin (Caelyx, Doxil) at a 6-week interval in patients with metastatic breast cancer. European Organization for Research and Treatment of Cancer.
Hamilton A; Biganzoli L; Coleman R; Mauriac L; Hennebert P; Awada A; Nooij M; Beex L; Piccart M; Van Hoorebeeck I; Bruning P; de Valeriola D
Ann Oncol; 2002 Jun; 13(6):910-8. PubMed ID: 12123337
[TBL] [Abstract][Full Text] [Related]
18. Weekly non-pegylated liposomal doxorubicin chemotherapy in heavily pre-treated patients with metastatic breast cancer.
Masci G; Gandini C; Zuradelli M; Losurdo A; Torrisi R; Rota S; Gullo G; Velutti L; Giordano L; Santoro A
Anticancer Res; 2013 Oct; 33(10):4603-9. PubMed ID: 24123037
[TBL] [Abstract][Full Text] [Related]
19. A study of pegylated liposomal Doxorubicin in platinum-refractory epithelial ovarian cancer.
Wilailak S; Linasmita V
Oncology; 2004; 67(3-4):183-6. PubMed ID: 15557776
[TBL] [Abstract][Full Text] [Related]
20. Metronomic administration of pegylated liposomal-doxorubicin in extensively pre-treated metastatic breast cancer patients: a mono-institutional case-series report.
Munzone E; Di Pietro A; Goldhirsch A; Minchella I; Verri E; Cossu Rocca M; Marenghi C; Curigliano G; Radice D; Adamoli L; Nolè F
Breast; 2010 Feb; 19(1):33-7. PubMed ID: 19884008
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]